An ‘Asia-first’ strategy for cosmetics and pharma maker Pierre Fabre; seeks to double regional revenue
The company is targeting about 60 million euros annual investment as it mulls expansion in Malaysia
Pierre Fabre, a cosmetics and pharmaceuticals company, is adopting an "Asia-first" strategy to double its revenue in the Asia-Pacific region by 2032. CEO Eric Ducournau revealed that the company is aiming to reach a revenue of nearly 5 billion euros (US$5.6 billion) globally by 2032. Presently, China and the Asia-Pacific (Apac) regions are deemed more significant to the company's global expansion efforts than the United States.
Ducournau highlighted that the Asia-Pacific region will play a larger role in the company's ambition to surpass five billion euros in global revenue. To achieve this, Pierre Fabre is planning to invest around 60 million euros annually in Malaysia, Vietnam, and other Asian markets. Ducournau emphasized the importance of developing their research and development portfolio in the pharmaceutical segment and expanding their international presence in Asia.
The company aims to quadruple its revenue in the region, with a focus on dermatology, rare diseases, and oncology. They are also considering expanding their manufacturing capacity in the region. The expansion into Asia is not a simple transplant of the company's European strategy, as the region's large population and genetic diversity require local clinical trials and partnerships with local patients and doctors.
Written by urgent.news from The Business Times - Companies & Markets's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
